Evidence map›Paper›PMID 40445758›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.

Alexander Leithner, Oskar Staufer, Tanmay Mitra, Falk Liberta, Salvatore Valvo, Mikhail Kutuzov, Hannah Dada, Jacob Spaeth, Weijie Zhou, Felix Schiele and 16 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Covalent tumor anchoring spatially orchestrates antitumor immunity.bioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Alexander Leithner *The Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.ORCID 0000-0002-1073-744X
Oskar Staufer *The Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.ORCID 0000-0002-8015-3132
Tanmay Mitra *The Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.
Falk Liberta *Boehringer Ingelheim Pharma GmbH & Co. Kg., Biberach an der Riss 88397, Germany.
Salvatore ValvoThe Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.
Mikhail KutuzovSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, United Kingdom.ORCID 0000-0003-3386-4350
Hannah DadaThe Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.
Jacob SpaethThe Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.
Weijie ZhouBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.
Felix SchieleBoehringer Ingelheim Pharma GmbH & Co. Kg., Biberach an der Riss 88397, Germany.
Sophia ReindlBoehringer Ingelheim Pharma GmbH & Co. Kg., Biberach an der Riss 88397, Germany.ORCID 0000-0002-7630-5199
Herbert NarBoehringer Ingelheim Pharma GmbH & Co. Kg., Biberach an der Riss 88397, Germany.ORCID 0000-0002-3878-6964
Stefan HoererBoehringer Ingelheim Pharma GmbH & Co. Kg., Biberach an der Riss 88397, Germany.ORCID 0000-0002-3259-7492
Maureen CramesBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.
Stephen ComeauBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.ORCID 0000-0003-4281-2026
David YoungBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.
Sarah LowBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.
Edward JenkinsThe Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.
Simon J DavisMedical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom.ORCID 0000-0002-2280-1170
David KlenermanDepartment of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom.ORCID 0000-0001-7116-6954
Andrew NixonBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.ORCID 0000-0002-6090-0583
Noah PefaurBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.
David WyattBoehringer Ingelheim Pharma GmbH & Co. Kg., Biberach an der Riss 88397, Germany.
Omer DushekSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, United Kingdom.ORCID 0000-0001-5847-5226
Srinath KasturiranganBiotherapeutics Discovery, Boehringer Ingelheim, Ridgefield, CT 06877.
Michael L DustinThe Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.ORCID 0000-0003-4983-6389

Funding

Austrian Science Fund (FWF) J4542-BChinese Academy of Medical Sciences (CAMS) 2018-I2M-2-002Kennedy Trust for Rheumatology Research (KTRR) KENN 20 21 17UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) BB/X015408/1Wellcome TrustWellcome Trust (WT) 207537/Z/Z17/Z
6 · The paper itself

Abstract

Bispecific T cell engagers (TcEs) link T cell receptors to tumor-associated antigens on cancer cells, forming cytotoxic immunological synapses (IS). Close membrane-to-membrane contact (≤13 nm) has been proposed as a key mechanism of TcE function. To investigate this and identify potential additional mechanisms, we compared four immunoglobulin G1-based (IgG1) TcE Formats (A-D) targeting CD3ε and Her2, designed to create varying intermembrane distances (A < B < C < D). Small-angle X-ray scattering (SAXS) and modeling of the conformational states of isolated TcEs and TcE-antigen complexes predicted close contacts (≤13 nm) for Formats A and B and far contacts (≥18 nm) for Formats C and D. In supported lipid bilayer (SLB) model interfaces, Formats A and B recruited, whereas Formats C and D repelled, CD2-CD58 interactions. Formats A and B also excluded bulky Quantum dots more effectively. SAXS also revealed that TcE-antigen complexes formed by Formats A and C were less flexible than complexes formed by Formats B and D. Functional data with Her2-expressing tumor cells showed cytotoxicity, surface marker expression, and cytokine release following the order A > B = C > D. In a minimal system for IS formation on SLBs, TcE performance followed the trend A = B = C > D. Addition of close contact requiring CD58 costimulation revealed phospholipase C-γ activation matching cytotoxicity with A > B = C > D. Our findings suggest that when adhesion is equivalent, TcE potency is determined by two parameters: contact distance and flexibility. Both the close/far-contact formation axis and the low/high flexibility axis significantly impact TcE potency, explaining the similar potency of Format B (close contact/high flexibility) and C (far contact/low flexibility).

Indexed as

Antibodies, BispecificImmunological SynapsesT-LymphocytesCD3 ComplexCell Line, TumorErb-b2 Receptor Tyrosine KinasesHumansImmunoglobulin GLipid BilayersReceptors, Antigen, T-CellScattering, Small AngleX-Ray DiffractionAntibodies, BispecificCD3 ComplexCD3E protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoglobulin GLipid BilayersReceptors, Antigen, T-Cellbreast cancerimmunological synapseimmunotherapymultistate modelingsupported lipid bilayers

Identifiers

PMID40445758
PMCPMC12146755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.